Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists


Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana, announced it is partnering with CPESN® USA in Ohio to expand access to pharmacists for its members

Acadia Healthcare Accelerates Access to Care With Uber Health: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Accelerates Access to Care With Uber Health


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER). The two companies are coming together to improve access to life-saving behavioral health

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence:
Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence


Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Chemed To Report First-Quarter 2024 Earnings April 24, Related Conference Call To Be Held On April 25:
Chemed To Report First-Quarter 2024 Earnings April 24, Related Conference Call To Be Held On April 25


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the

Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

Agilent Launches New Advanced Dilution System to Increase Lab Efficiency:
Agilent Launches New Advanced Dilution System to Increase Lab Efficiency


Agilent Technologies Inc. (NYSE: A) today announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of

Novocure to Report First Quarter 2024 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report First Quarter 2024 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on

Poxel to Report Its 2023 Annual Results by the End of April 2024: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel to Report Its 2023 Annual Results by the End of April 2024


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs


Novocure (NASDAQ: NVCR) gab heute bekannt, dass die klinische Phase-3-Studie METIS ihren primären Endpunkt erreicht hat und eine statistisch signifikante Verbesserung der Zeit bis zur

Acadia Healthcare Acquires Three Comprehensive Treatment Centers in North Carolina: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Acquires Three Comprehensive Treatment Centers in North Carolina


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has recently completed the acquisitions of three comprehensive treatment centers (“CTC”) in North Carolina.



Two of the

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting: https://mms.businesswire.com/media/20231018100004/en/1918576/5/Personalis_Logo.jpg
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®

EQS-News: MEDICLIN Herzzentrum Coswig: Transfer of operations on 1 April
EQS-News: MEDICLIN Herzzentrum Coswig: Transfer of operations on 1 April
EQS-News: MEDICLIN Herzzentrum Coswig: Transfer of operations on 1 April
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update: https://mms.businesswire.com/media/20230215005587/en/545518/5/OSE_LOGO_Horizontal_RVB.jpg
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical

Uni-Bio Science Group Announces 2023 Annual Results
Uni-Bio Science Group Announces 2023 Annual Results
Uni-Bio Science Group Announces 2023 Annual Results
Charles River Laboratories Publishes 2023 Corporate Citizenship Report: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Publishes 2023 Corporate Citizenship Report


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for

EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Resolutions of the Annual Shareholders’ Meeting  of Sartorius Stedim Biotech S.A.
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.